Publication for CDH1 and PRSS8

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CDH1	cadherin 1	999			[link]
hsa	PRSS8	serine protease 8	5652

Pubmed ID	Priority	Text
19849847	0.98	E-cadherin protein expression information on the MDA TCC cell lines was recently reported by Black et al.. The prostasin-positive MDA TCC cell lines, UM-UC-5, -9, -10, and -14, were shown to express a high abundance of E-cadherin at the protein level, and were also all epithelial in appearance in culture.
	0.98	prostasin-negative 253J P, 253J B-V and UM-UC-12 cell lines express the E-cadherin protein at low to medium levels (Figure 2B, and) and are mesenchymal-like in culture (Figure 3).
	0.98	prostasin and E-cadherin are shown in Figure 4.
	0.98	prostasin mRNA, all but one (UM-UC-10) expressed the E-cadherin mRNA at above the median level (Figure 4).
	0.98	prostasin mRNA, all but two (UM-UC-6 and 253J B-V) expressed the E-cadherin mRNA at below the median level, and four lines were negative (Figure 4).
	0.98	prostasin and E-cadherin expression, and cell morphology are summarized in Table 2.
	0.98	prostasin or a serine active-site mutant variant in KU-7 was associated with E-Cadherin mRNA up-regulation
	0.98	prostasin protein was expressed at similar levels (Figure 7A), the E-cadherin mRNA was up-regulated by ~50% by the wild-type or the mutant prostasin (Figure 7B).
	0.98	E-cadherin transcription is up-regulated by prostasin re-expression could be impacted by epigenetic modifications in the E-cadherin promoter, events that are common in cancer cells.
	0.97	prostasin and E-cadherin mRNA expression, respectively, shown as relative levels per GAPDH mRNA copy.
	0.97	prostasin protein or mRNA expression is also strongly associated with below-median level E-cadherin mRNA expression, in 7 out of 9 lines (Figure 4).
	0.97	E-cadherin protein expression (+++), UM-UC-6, is negative for prostasin expression.
	0.97	prostasin expression was also observed for the prostasin/E-cadherin double-negative T24 cell line, which is mesenchymal in morphology, with an up-regulation of the prostasin mRNA (data not shown).
	0.97	E-cadherin by prostasin or the protease-inactive variant could be recapitulated in the KU-7 cells (Figure 7), though not as robust as that seen previously with the PC-3 cells.
	0.97	prostasin expression knock-down may not have been sufficient to affect E-cadherin expression.
	0.97	prostasin is associated with the epithelial-mesenchymal transition (EMT), marked by a loss of or a reduced E-cadherin expression.
	0.96	prostasin re-expression in a TCC cell line could result in E-cadherin up-regulation, as we have observed previously for the human prostate cancer cell line PC-3, we infected the KU-7 cell line with lentiviruses driving the expression of the wild-type human prostasin (Pro), or a serine active-site mutant variant prostasin (ProM).
	0.95	prostasin expression state and cell morphology is manifested at the two end points of this progression, i.e., the starting end of epithelial morphology and prostasin/E-cadherin expression, and the EMT end of mesenchymal morphology and loss of prostasin with reduced or loss of E-cadherin expression.
	0.94	prostasin-negative MDA TCC cell lines, UM-UC-6 and -13, were shown not to express E-cadherin and to have mesenchymal-like morphology in culture by Black et al.. These two cell lines also appeared mesenchymal in culture in our hands (Figure 3), but the UM-UC-6 cells expressed E-cadherin at the protein level (Figure 2B).
	0.94	E-cadherin expression, prostasin expression may also correlate with urothelial cancer sensitivity to cetuximab.
	0.93	prostasin expression by at least 50% and up to 75%, in five urothelial cell lines, UROtsa, HT-1376, RT4, UM-UC-5, and UM-UC-9, but the prostasin expression knock-down was not associated with E-cadherin down-regulation (data not shown).
	0.93	prostasin expression over many generations of cell division to have a significant impact on E-cadherin expression and cell morphology seen in the prostasin-negative TCC cell lines.
	0.92	prostasin in the urothelial cells is associated with the epithelial state, marked by abundant E-cadherin expression.
	0.91	prostasin-negative J82, T24, and UM-UC-3 cells all appear as spindle-shaped single cells or clusters without well defined cell-cell contacts in low-density cultures (Figure 3), i.e., fibroblastic or mesenchymal, and do not express E-cadherin at the protein level (Figure 2A).
	0.89	prostasin, E-cadherin, and GAPDH (as a control for sample loading) in the urothelial cell lines.
	0.87	prostasin expression in the TCC cell lines correlated with loss of or reduced E-cadherin expression, loss of epithelial morphology, and promoter DNA hypermethylation.
	0.87	prostasin-negative KU-7 cell line, which does not express E-cadherin but is epithelial in appearance (Figure 2A and Figure 3), as previously noted by Black et al..
	0.87	E-cadherin mRNA up-regulation solely to the up-regulation of prostasin because these two epigenetic modulating agents have a direct impact on the E-cadherin promoter.
	0.87	prostasin or a serine protease-inactive mutant could up-regulate E-cadherin expression via a transcriptional mechanism.
	0.86	prostasin and E-cadherin expression by western blot and quantitative PCR, and for prostasin gene promoter region CpG methylation by methylation-specific PCR (MSP).
	0.85	Prostasin and Protease-inactive Variant in KU-7 Cells Up-regulates E-cadherin Transcription.
	0.82	prostasin expression could still be associated with a high abundance of E-cadherin expression, as seen with the RT4 cells (Figure 2B and Figure 4).
	0.79	Prostasin protein or mRNA expression in the urothelial cells is 100% associated with the epithelial morphology, and with the most abundant E-cadherin protein expression (+++).
	0.69	Prostasin and E-cadherin mRNA Expression in Urothelial Cells Evaluated by qRT-PCR.
	0.66	prostasin, E-cadherin, and EGFR expression.
	0.52	prostasin or a serine protease-inactive variant resulted in transcriptional up-regulation of E-cadherin.
31998788	0.98	CDH1, KRAS, ESRP1, AP1M2, CLDN4, PRSS8, and RAB25).
	0.78	CDH1, PRSS8, RAB25, MAL2, and AP1M2) (Figure 2(c)) as well as 5 hub genes (GNAS, ANGPT1, RECK, KRAS, and PRKAR1A) in module 2 (Figure 2(d)).
15685234	0.98	prostasin (Chen and Chai, 2002), E-cadherin (Melki et al, 2000; Nakayama et al, 2001), normal epithelial cell-specific 1 (NES1) (Li et al, 2001) and COX-2 (Kikuchi et al, 2002).
22761798	0.98	PRSS8, KRT15, CLDN7, and CDH1.
23251436	0.98	CDH1, CXADR, PRSS8 and SYK, several downregulated epithelial cell markers such as EPCAM, JUP, KRT15, KRT17, OCLN, PKP2 and PPL and a number of downregulated tumor suppressors such as KLK10, MTUS1, OAS1 and SERPINB1.
24940735	0.98	CDH1, ADAP1, CAMSAP3); interactions at desmosomes (PPL, PKP3, JUP); transcription regulation of cell-cell junction complexes (GRHL1 and 2); epithelial RNA splicing regulators (ESRP1 and 2); epithelial vesicle traffic (RAB25, EPN3, GRHL2, EHF, ADAP1, MYO5B); epithelial Ca(+2) signaling (ATP2C2, S100A14, BSPRY); terminal differentiation of epithelial cells (OVOL1 and 2, ST14, PRSS8, SPINT1 and 2); maintenance of apico-basal polarity (RAB25, LLGL2, EPN3).
28472783	0.98	PRSS8 overexpression led to the upregulation of P21 and E-cadherin and to the downregulation of cyclin D1, Twist and Snail in KYSE450 and EC9706 cells.
30282996	0.98	E-cadherin, LATS2, PRSS8, KLF2, NKD2).
27081034	0.97	PRSS8 overexpression led to the upregulation of P21 and E-cadherin and to the downregulation of cyclin D1, Twist and Snail in KYSE450 and EC9706 cells.
	0.97	PRSS8 expression, upregulated P21 and E-cadherin expression, and downregulated the expression of Cyclin D1, Twist and Snail.
	0.93	PRSS8 led to the alterations of cell proliferation-related proteins (i.e. increase of P21WAF1 and decrease of Cyclin D1), and led to the alterations of epithelial-mesenchymal transition (EMT)-related proteins (e.g. upregulation of E-cadherin and downregulation of Twist and Snail) in KYSE450 and EC9706 cells.
23353098	0.97	prostasin expression in cell lines, with concomitant reactivation of E-cadherin and recovery of epithelial morphology.
25706888	0.97	CDH1, KRT8, KRT18, ST14, PRSS8, DSP, OCLN, SCNN1A, SPINT1, SPINT2 and TJP3) were over-expressed in BRCA tumors as compared with normal tissues.
26317012	0.97	prostasin/PRSS8, modulates EGFR signalling via enhancement of matriptase cleavage of the EGFR extracellular domain (ECD) and regulates SLUG and E-cadherin expression in cancer cells.
20181230	0.96	prostasin a serum marker for ovarian cancer; (2) Mesothelin (MSLN), (3) WFDC2 (HE4) a glycoprotein (4) osteopontin; (5) Bikunin; (6) mammaglobin-2 (MGB2); (7) discoidin domain receptor 1 (DDR1); (8) claudin 3 (CLDN3); (9) epithelial cell adhesion molecule (Ep-CAM); and (10) E-cadherin.
27258544	0.95	Cdh1, Cdh2, Epcam, Fn1, Lox, Mmp2, Ocln, Prss8, Vcan, Vim, and Zeb1, were in common in all the three lists and only 95 genes were in common in at least two of the three lists (Table 1).
	0.88	Cdh1, Cdh2, Epcam, Fn1, Lox, Mmp2, Ocln, Prss8, Vcan, Vim, and Zeb1 were identified in PO-list, EM-list, and SC-list (Fig 1C).
30642115	0.69	PRSS8 was found to be downregulated by promoter methylation in high-grade BlCa tissues, and its overexpression in cell lines was associated with E-Cadherin upregulation, which suggests an interplay between these two proteins during epithelial differentiation.
29158785	0.68	CDH1, CDH13, CDKN2A, FABP3, FHIT, GIB2, GPC3, GSTP1, HOXA5, HSHIN1, KLK10, NME1, PRDM2, PRKCDBP, RARB, RASSF1, SFN, SYK, TFF1, TIMP3 and WT1; and quite a few cases show inconsistency between cell lines and tumors, e. g. , IL6, GSN, PLAU, PRSS8, SLC19A1, SNCG are hypermethylated in tumors but not in cell lines and the hypermethylation of PLAGL1, TGFB3 is observed in cell lines but not tumors.